CorFlow to Report Company’s Clinical Progress to LifeScience Investors at LSX and Swiss Nordic Bio Conferencesadmin
CorFlow to Report Company’s Clinical Progress to Life Science Investors at the LSX and Swiss Nordic Bio Conferences
Baar, Switzerland, February 3rd 2020
CorFlow Therapeutics AG (“CorFlow”) will this week present the company during the LSX World Congress in London, UK, and the Swiss Nordic Bio conference in Zürich, Switzerland.
The company presentations will be made by CorFlow’s CEO and co-Founder, Jon H. Hoem.
The presentations will highlight the milestones achieved by the company over the last months. The US Food and Drug Administration (FDA) recently granted Breakthrough Device Designation for the CorFlow Controlled Flow Infusion (CoFI) System. Consequently, the company filed for an Early Feasibility Study (EFS) which, when approved, will enable the company to enroll the first US patients using the first generation CoFI System. In the European First-in-Man MOCA I trial, the company has now enrolled a total of 17 patients of which 12 are acute heart attack patients (STEMI). These patients have been enrolled at the University Hospital of Bern (Inselspital) and CorFlow will shortly start to enroll patients at other Swiss university hospitals including the University Hospital of Lausanne (CHUV) and the University Hospital of Geneva. In addition, the presentation will describe the substantial market opportunity which the diagnosis and treatment of Microvascular Obstruction (MVO) constitutes and how the CoFI System addresses this need.
For the last 5 years, the LSX World Congress has been bringing together the executives that matter for the future of healthcare and life science business strategy, investment, partnering, deal making and commerciali-sation. The congress gathers the founders and CEOs of innovative start-ups through publicly listed life science giants, and everyone in between. It represents the breadth and the depth of the cutting-edge research and technology driving advances in the healthcare industry right now and in the future.
Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting healthcare innovations, investors and industry. The conference is the number one platform that gathers life science professionals from Switzerland and the Nordic countries under one roof.